KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maxlinear (MXL) Research & Development (2016 - 2025)

Maxlinear (MXL) has disclosed Research & Development for 16 consecutive years, with $51.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 0.81% to $51.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $208.6 million, a 7.37% decrease, with the full-year FY2025 number at $208.6 million, down 7.37% from a year prior.
  • Research & Development was $51.7 million for Q4 2025 at Maxlinear, down from $54.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $80.4 million in Q2 2022 to a low of $47.2 million in Q2 2025.
  • A 5-year average of $63.9 million and a median of $65.6 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 165.92% in 2021, then decreased 21.41% in 2024.
  • Maxlinear's Research & Development stood at $73.3 million in 2021, then increased by 0.55% to $73.7 million in 2022, then dropped by 11.49% to $65.2 million in 2023, then fell by 21.41% to $51.3 million in 2024, then rose by 0.81% to $51.7 million in 2025.
  • Per Business Quant, the three most recent readings for MXL's Research & Development are $51.7 million (Q4 2025), $54.3 million (Q3 2025), and $47.2 million (Q2 2025).